Dosing Begins in ACU193 Trial, Targeting Toxic Amyloid Beta

Dosing Begins in ACU193 Trial, Targeting Toxic Amyloid Beta

309532

Dosing Begins in ACU193 Trial, Targeting Toxic Amyloid Beta

The first patient has been dosed in a Phase 1 trial testing ACU193, an antibody designed by Acumen Pharmaceuticals to target toxic forms of amyloid beta — called amyloid-beta oligomers — as a potential therapy for early Alzheimer’s disease. The INTERCEPT-AD Phase 1 trial (NCT04931459) is expecting to enroll approximately 62 patients, ages 55-85, with mild cognitive impairment or mild dementia due to Alzheimer’s disease, across six clinical sites in Arizona, Florida, Georgia, and Ohio. Recruitment…

You must be logged in to read/download the full post.